Need some fitspiration?

134710-067-022Our #FitnessFriday inspiration comes from Stephanie Rubin and Laura Feidelson. They ran the Pinehurst, North Carolina Turkey Trot Half Marathon in 2 hours and 7 minutes, and ended up raising almost $12,500 for our research programs in honor of a loved one!

“When my father was diagnosed with prostate cancer, he was lucky enough to end up in the very competent hands of Dr. Mitchell Benson who got the situation under control.  I was so inspired by Dr. Benson and so grateful that I decided to run this half marathon and donate to the T.J. Martell Foundation prostate cancer research to hopefully help him continue to save lives.  I am just so honored to have contributed to such an incredible foundation and I hope to run many more races for T.J. Martell in the future,” says Stephanie.

Please join us in congratulating and thanking these inspiring young women!

Marathon Girls 3

How Your Support Helps Fund Prostate Cancer Research

DonTindallMayo - small

Donald J. Tindall, Ph.D. is the Carl Rosen Professor in Urology, Departments of Urology, Biochemistry Molecular Biology, Mayo Clinic College of Medicine.

“Funding from the T.J. Martell Foundation has been significantly relevant to my research efforts during the past 15 years. This is particularly true over the past 5 years when federal funding has been very scarce. Support from the T.J. Martell Foundation has allowed my laboratory to pursue novel and high risk studies for a better understanding of prostate cancer progression.

Furthermore, this funding has contributed to the professional development of a number of young investigators who are pursuing careers in prostate cancer research. Much of their success can be attributed to funding from the T.J. Martell Foundation. Now, many of these young investigators hold independent research positions as principal investigators at prestigious universities and research institutes. We are grateful for the support of the T.J. Martell Foundation for our efforts to understand the pathobiology of prostate cancer, to define markers for prognosis and to develop novel therapeutics against this devastating disease,” says our funded researcher, Donald Tindall, M.D. of Mayo Clinic.

Hats Off to Dad!

originalThis Sunday is Father’s Day, and we’re proud to be partnering with the team at Listia to raise funds for prostate cancer research through an exclusive online auction featuring hats and albums autographed by beloved celebrities like Thompson Square, Jason Aldean, Kellie Pickler, Kelsea Ballerini, Joe Nichols, and many more. Click here for more details and place your bid today!

original-2

“The Greatest Reassurance I Can Give to Any Man…”

“We’ve made significant progress in prostate cancer treatments and quality of life for patients over the past five years. My colleagues and I commend the T.J. Martell Foundation for their continued support and appreciate their demonstrated commitment to funding innovative research,” says Mitchell Benson, M.D., Emeritus Chair, Department of Urology, Columbia University Medical Center., who will be receiving our Scientific Achievement Award for Excellence at our New York Golf Classic on July 20th.

Please watch this quick video for an important message from Dr. Benson about prostate cancer.

A Fun Way to Give Back with Listia!

photo-1421986527537-888d998adb74Exciting news – we’re honored to be one of Listia’s designated charities for the month of June! Listia is a marketplace where you can trade things you don’t need anymore for stuff you want. It’s all free with no money involved. How cool is that?

With Listia’s monthly Charity Program, all members are encouraged to donate funds to charity without spending any money whatsoever. Members are able to donate a few of their Listia Credits to our foundation. While members donate their Credits, Listia matches those credits with real money which is then donated once the month is complete.

Since June is Prostate Cancer Awareness month, we will direct all funds raised through our partnership with Listia to our excellent prostate cancer research programs at Mayo Clinic, Mount Sinai School of Medicine, and Columbia University Medical Center. Please click here to learn more and help support our prostate cancer research!

Thanks so much to our friends at Listia for their generous support!

Prostate Cancer Breakthrough at Mount Sinai Hospital

T.J. Martell Foundation-supported scientists have identified a “master regulator” gene driving aggressiveness in prostate cancer.

Scientists at Mount Sinai Hospital in New York, with the support of the T.J. Martell Foundation, have discovered a gene that acts as a switch and activates the aggressiveness of tumor cells. The discovery could have a major impact on the development of treatments for prostate cancer.

Prostate cancer is the most common tumor and one of the leading causes of cancer death in men. In about 10-15% of patients prostate cancer has an aggressive disease course characterized by the appearance of tumors in distant organs (metastasis) and the acquisition of resistance to anticancer drugs, which contributes to the death of most patients with prostate cancer.

The study, led by Dr. Josep Domingo-Domenech published and highlighted in the cover of the prestigious scientific journal Cancer Cell, describes a mechanism by which prostate cancer cells become aggressive and survive standard treatment. The key is a gene called GATA2, which encodes a transcription factor capable of reprogramming and activating aggressive cells through activation of multiple signaling pathways.

Using computational biology techniques that integrate genetic information from prostate cancer cells in humans and experimental models it has been possible to identify the master regulator gene GATA2. It was observed that experimental prostate cancer tumor cells with high levels of GATA2 initiated aggressive tumors that were resistant to chemotherapy. GATA2 gene acts as a master gene, controlling the activation and expression of many other genes. It activates other genes, putting them to work invading healthy tissue and initiating metastasis. Other genes are set to activate survival pathways that help initiate tumors and make cells resistant to anticancer drugs. This is the case for the gene coding the growth factor IGF2, which is activated directly by GATA2 triggering a signaling cascade that increases tumor cell survival under adverse conditions.

Importantly the discovery of the master gene, GATA2, that regulates expression of IGF2 led to the identification of a new therapeutic strategy for patients with prostate cancer. The new treatment strategy combines chemotherapy with IGF2 pathway inhibitors which improves the results of chemotherapy and allows more durable responses. Dr. Domingo- Domenech explains, ‘the combination of chemotherapy with IGF2 pathway inhibitors helps enhance the antitumor effect of chemotherapy and was well tolerated in animal models. Now we are looking forward to translate these studies into patients.”

“This important finding is a clear example of the excellent science with important clinical implications for cancer patients that the T.J. Martell Foundation is currently funding,” says Dr. James Holland, the founding research scientist for the T.J. Martell Foundation. The support that the T.J. Martell Foundation has given Dr. Domingo- Domenech during the last years is helping enormously to uncover new therapeutic targets against this devastating disease.